ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting

    Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial

    Erik Eriksen1, Roland Chapurlat 2, Rogely Boyce 3, Jacques Brown 4, Stéphane Horlait 5, Cesar Libanati 6, Yifei Shi 3, Rachel Wagman 3 and Pascale Chavassieux 2, 1Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, 2INSERM UMR 1033, Université de Lyon, Lyon, France, 3Amgen Inc., Thousand Oaks, CA, 4CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, 5Amgen Inc., Boulogne Billancourt, France, 6UCB Pharma, Brussels, Belgium

    Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
  • Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting

    Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study

    Xanthe ME Matthijssen1, Ellis Niemantsverdriet 2, Thomas Huizinga 2 and Annette van der Helm-van Mil 3, 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
  • Abstract Number: 250 • 2019 ACR/ARP Annual Meeting

    Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US

    Robin Dore1, Jenya Antonova 2, Chakkarin Burudpakdee 3, Lawrence Chang 2, Jing He 4 and Mark Genovese 5, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3IQVIA, Falls Church, VA, 4IQVIA, Plymouth meeting, PA, 5Stanford University, Stanford, CA

    Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
  • Abstract Number: 543 • 2019 ACR/ARP Annual Meeting

    Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients

    Sergio Duran-Barragan1, Efrain Chavarria-Avila 1, Marisol Esesarte-Rodriguez 1, Rosal Valenzuela-Marrufo 1, Karla Arrona-Ríos 1, Jorge Aguilar-Arreola 1, Oscar Pizano Martínez 1 and Monica Vazquez-del Mercado 1, 1Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

    Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T…
  • Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting

    Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

    Robin Dore1, Jenya Antonova 2, Leslie Harrold 3, Lawrence Chang 2, Emily Scherer 4, Angel Cronin 5, Kelechi Emeanuru 5 and Joel Kremer 6, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, 4Corrona, LLC, Cambridge, MA, 5Corrona, LLC, Waltham, MA, 6Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
  • Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting

    Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients

    Ankita Singh1, Harikrishnan Nair 2, Vikas Gupta 2, Pradeepta Sekhar 2, Ramnath Misra 3 and Amita Aggarwal 4, 1Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
  • Abstract Number: 402 • 2019 ACR/ARP Annual Meeting

    Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy

    Océane Landon-Cardinal1, Kuberaka Mariampillai 2, Céline Anquetil 3, Aude Rigolet 2, Baptiste Hervier 4, Nicolas Champtiaux 2, Olivier Benveniste 3 and Yves Allenbach 3, 1Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 2Pitié-Salpêtrière University Hospital, Paris, France, 3Sorbonne Université, Paris, France, 4Hopital Pitie-Salpetriere, Paris, France

    Background/Purpose: Anti-HMGCR antibodies have been associated with a severe form of immune-mediated necrotizing myopathy (IMNM) with a poor muscle strength recovery and early muscle damage.…
  • Abstract Number: 550 • 2019 ACR/ARP Annual Meeting

    Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study

    Arthur Kavanaugh1, Rene Westhovens 2, Kevin Winthrop 3, Susan Lee 4, Joy Greer 4, Adam DeZure 4, Di An 4, Lei Ye 4, John Sundy 4, Robin Besuyen 5, Luc Meuleners 5, Rieke Alten 6 and Mark Genovese 7, 1University of California, San Diego School of Medicine, La Jolla, CA, 2University Hospitals, Leuven, Belgium, 3Oregon Health and Science University, Portland, OR, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Schlosspark-Klinik University Medicine, Berlin, Germany, 7Stanford University, Stanford, CA

    Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
  • Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

    Mochihito Suzuki1, Toshihisa Kojima 2, Nobunori Takahashi 2, Shuji Asai 2 and Naoki Ishiguro 2, 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose:  In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
  • Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting

    A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients

    Peter Taylor1, Bryan Downie 2, Emon Elboudwarej 3, Rachael Hawtin 3, Amer M. Mirza 3 and Jinfeng Liu 3, 1University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster Citty, CA, 3Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
  • Abstract Number: 473 • 2019 ACR/ARP Annual Meeting

    RA Presents in Disease Patterns Impacting Treatment Response

    Kathryne Marks1, Dana Symons 2, Cynthia Crowson 3, Pamela Sinicrope 4 and Kelly O'Neill 5, 1Rosalind Franklin University of Medicine and Science, Gurnee, IL, 2Rheumatoid Patient Foundation, Inc., Rockford, MI, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, MN, 5Rheumatoid Patient Foundation, Inc., Winter Springs, FL

    Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
  • Abstract Number: 557 • 2019 ACR/ARP Annual Meeting

    Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

    Theresa Hunter1, David Sandoval 2, Nicola Booth 3, Elizabeth Holdsworth 4 and Atul Deodhar 5, 1Eli Lilly and Company, Indianapolis, 2Eli Lilly and Company, Indianapolis, IN, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Manchester, England, United Kingdom, 5Oregon Health & Science University, Portland, OR

    Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
  • Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting

    Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis

    Aniela Croiteru 1, Merav Lidar 2, Tatiana Reitblat3, Devy Zisman 4, Alexandra Balbir-Gurman 5, Tanya Meshiach 5, Ronit Almog 5 and Ori Elkayam 6, 1Tel Aviv medical center, Tel Aviv, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Barzilai Medical Center, Ashkelon, Israel, 4Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, 5Rambam Medical Center, Haifa, Israel, 6Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel

    Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited.  We sought to analyze…
  • Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting

    Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)

    Shuji Asai1, Toshihisa Kojima 1, Nobunori Takahashi 1 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
  • Abstract Number: 504 • 2019 ACR/ARP Annual Meeting

    A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

    Kenneth Kalunian1, Mark Genovese 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, Alena Pechonkina 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, Kurt de Vlam 6, David Walker 7 and Tsutomu Takeuchi 8, 1Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 2Stanford University, Stanford, CA, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 7Northumbria Healthcare, Northumbria, United Kingdom, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology